SARS	Severe acute respiratory syndrome
MERS	Middle East respiratory syndrome
COVID-19	Coronavirus Disease 2019
SARS-CoV-2	SARS coronavirus 2
2019-nCoV	Novel coronavirus 2019
HCoV-19	Human coronavirus 2019
SARSr-CoV	SARS-related coronavirus
NTD	N-terminal domain
CTD	C-terminal domain
RBD	Receptor-binding domain
ACE2	Angiotensin-converting enzyme 2
APN	Aminopeptidase N
DPP4	Dipeptidyl peptidase 4
CPL	Cysteine protease cathepsin L
TMPRSS2	Transmembrane protease serine 2
FP	Fusion peptide
6-HB	Six-helix bundle
PRNT	Plaque reduction neutralization test
IFITM	Interferon-inducible transmembrane
NM	Nafamostat mesylate
FOY	Ggabexate mesylate
IC50	50% inhibitory concentration
CC50	50% cell cytotoxicity concentration
EC50	Concentration for 50% of maximal effect
EC90	Concentration for 90% of maximal effect
RAS	Renin-angiotensin system
AT2	Angiotensin II receptor
pan-CoV	Pan-coronavirus